Authors: Tomáš Fait 1; B. Trnková 3; M. Koštířová 3; M. Vráblík 2 Authors‘ workplace: Gynekologicko-porodnická klinika VFN Praha a 1. LF UK, Praha, přednosta prof. MUDr. A. Martan, DrSc. 1; III. interní klinika VFN Praha a 1. LF UK, Praha, přednosta prof. MUDr. Š. Svačina, DrSc. 2; Ústav klinické biochemie VFN Praha a l. LF UK, Praha, přednosta prof. MUDr. T. Zima, DrSc. 3 Published in: Ceska Gynekol 2007; 72(5): 343-347 Category: Original Article
Objective: The purpose of the present study was to determine changes of tissue factor pathway inhibitor (TFPI) as a biochemical risk factors of thromboembolism during the use of different administration methods of the early estrogen replacement therapy.
Design: Prospective randomized cross-over trial.
Setting: General Faculty Hospital Prague.
Methods: In a 12-week prospective, randomized, interventional, cross-over trial, estradiol was administered orally in a dose of 2 mg daily or transdermally in a dose of 0,05 mg daily. Forty-five healthy postmenopausal women were included into the study within 12 weeks after the hysterectomy and ovariectomy (surgical castration). Forty-one women completed the study and their data were analyzed. The average age was of 49 ± 6 years. An enzymatic method (IMUBIND Total TFPI ELISA test) was employed for the determination of TFPI.
Results. After the oral therapy, the average value of TFPI decreased statistically significantly (p
Key words: estrogen replacement therapy, thromboembolism, TFPI
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
